MLXIPL and fatty liver disease: Additional analyses of participants with diagnosed hepatic steatosis and at least 1 of 5 metabolic dysfunction–associated steatotic liver disease (MASLD)-defining cardiovascular risk factors showed a significantly higher risk for metabolic dysfunction–associated steatotic liver disease in homozygous MLXIPL Gln241His carriers (Table 2 and Supplemental Table S12, http://links.lww.com/HC9/A866).